Detalhe da pesquisa
1.
Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study.
Clin Gastroenterol Hepatol
; 2024 Mar 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-38447814
2.
An integrated analysis of fecal microbiome and metabolomic features distinguish non-cirrhotic NASH from healthy control populations.
Hepatology
; 78(6): 1843-1857, 2023 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37222264
3.
Non-invasive evaluation of response to obeticholic acid in patients with NASH: Results from the REGENERATE study.
J Hepatol
; 76(3): 536-548, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34793868
4.
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial.
Lancet
; 394(10215): 2184-2196, 2019 12 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31813633
5.
Factors Associated With Histologic Response in Adult Patients With Nonalcoholic Steatohepatitis.
Gastroenterology
; 156(1): 88-95.e5, 2019 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30222962
6.
Relationship between three commonly used non-invasive fibrosis biomarkers and improvement in fibrosis stage in patients with non-alcoholic steatohepatitis.
Liver Int
; 39(5): 924-932, 2019 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-30253043
7.
CONTROL: A randomized phase 2 study of obeticholic acid and atorvastatin on lipoproteins in nonalcoholic steatohepatitis patients.
Liver Int
; 39(11): 2082-2093, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31402538
8.
A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis.
JHEP Rep
; 5(1): 100563, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36644237
9.
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo-controlled, phase 2b trial.
Lancet Gastroenterol Hepatol
; 8(12): 1080-1093, 2023 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-37802088
10.
Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors.
Cancer Cell
; 5(3): 221-30, 2004 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15050914
11.
Janus kinase inhibitor INCB20 has antiproliferative and apoptotic effects on human myeloma cells in vitro and in vivo.
Mol Cancer Ther
; 8(1): 26-35, 2009 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-19139110
12.
Alosetron versus traditional pharmacotherapy in clinical practice: effects on resource use, health-related quality of life, safety and symptom improvement in women with severe diarrhea-predominant irritable bowel syndrome.
Curr Med Res Opin
; 35(3): 461-472, 2019 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-30293448
13.
REGENERATE: Design of a pivotal, randomised, phase 3 study evaluating the safety and efficacy of obeticholic acid in patients with fibrosis due to nonalcoholic steatohepatitis.
Contemp Clin Trials
; 84: 105803, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31260793
14.
Retraction: Insulin-like Growth Factor-1 Induces Adhesion and Migration in Human Multiple Myeloma Cells via Activation of ß1-Integrin and Phosphatidylinositol 3'-Kinase/AKT Signaling.
Cancer Res
; 84(6): 938, 2024 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38486484
15.
Effects of PS-341 on the activity and composition of proteasomes in multiple myeloma cells.
Cancer Res
; 65(17): 7896-901, 2005 Sep 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16140960
16.
Blockade of Hsp27 overcomes Bortezomib/proteasome inhibitor PS-341 resistance in lymphoma cells.
Cancer Res
; 63(19): 6174-7, 2003 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-14559800
17.
Caveolin-1 is required for vascular endothelial growth factor-triggered multiple myeloma cell migration and is targeted by bortezomib.
Cancer Res
; 64(20): 7500-6, 2004 Oct 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-15492276
18.
Proteasomal degradation of topoisomerase I is preceded by c-Jun NH2-terminal kinase activation, Fas up-regulation, and poly(ADP-ribose) polymerase cleavage in SN38-mediated cytotoxicity against multiple myeloma.
Cancer Res
; 64(23): 8746-53, 2004 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-15574786
19.
Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3'-kinase/AKT signaling.
Cancer Res
; 63(18): 5850-8, 2003 Sep 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-14522909
20.
Blockade of ubiquitin-conjugating enzyme CDC34 enhances anti-myeloma activity of Bortezomib/Proteasome inhibitor PS-341.
Oncogene
; 23(20): 3597-602, 2004 Apr 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-15094775